Loading...
XNAS
ATRA
Market cap84mUSD
Oct 08, Last price  
9.23USD
1D
-1.49%
1Q
-5.43%
Jan 2017
-97.40%
IPO
-96.92%
Name

Atara Biotherapeutics Inc

Chart & performance

D1W1MN
XNAS:ATRA chart
P/E
2.54
P/S
0.69
EPS
3.63
Div yield, %
—
Shrs. gr., 5y
33.86%
Rev. gr., 5y
%
Revenues
121m
-6.33%
00000000020,340,00063,573,0008,573,000128,940,000120,772,000
Net income
33m
P
-123,300,000-87,730,000-280,060,000-572,210,000-790,490,000-1,194,910,000-2,306,990,000-290,976,000-306,620,000-340,141,000-228,302,000-276,126,000-85,403,00032,688,000
CFO
-51m
L-25.87%
-2,475,000-5,966,000-16,628,000-37,156,000-60,025,000-87,502,000-179,772,000-235,626,000-180,759,000-220,522,000-270,430,000-192,977,000-68,717,000-50,940,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Key people

Jill Henrich
Executive Vice President - Global Head Regulatory Affairs and Quality · since 2023
Carol Gallagher
Lead Independent Director · since 2024
Anhco Nguyen
President, Chief Executive Officer, Director · since 2024
Gregory Ciongoli
Non-Executive Chairman of the Board · since 2025
Matthew Fust
Independent Director · since 2014
William Heiden
Independent Director · since 2015
James Huang
Independent Director · since 2025
Nachiappan Subramanian
Independent Director · since 2025
URL
https://www.atarabio.com
IPO date
Oct 16, 2014
Employees
317
Domiciled in
US
Incorporated in
US
Legal address
C/O Incorporating Services, Ltd.
3500 South DuPont Highway
Dover, DE 19901
US
Headquarters
3260 Bayshore Boulevard
Brisbane, CA 94005
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT